I had no idea this could happen. I wouldn’t have done it,” New Jersey-based former Mounjaro user James Norris, who is now visually impaired, told The Post ...
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
1d
HealthDay on MSNMakers of Wegovy & Zepbound Cut Prices for Those Without InsuranceKey Takeaways Novo Nordisk cut Wegovy’s price to $499 per month, a 23% decreaseEli Lilly lowered Zepbound’s starter dose to ...
Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
1d
Zacks Investment Research on MSNPharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & MoreBayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Novo Nordisk's rare disease unit awaits Phase 3 data for etavopivat in sickle cell disease, aiming for 50% VOC reduction ...
The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...
Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly lucrative ...
Novo Nordisk is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical companies next week. CEO Lars Jørgensen told reporters Thurs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results